Mon, Sep 22, 2014, 6:50 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

DexCom, Inc. (DXCM) Message Board

mikerogersjr1 2 posts  |  Last Activity: Jan 7, 2013 11:04 AM Member since: Dec 17, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mikerogersjr1 by mikerogersjr1 Jan 7, 2013 11:04 AM Flag

    I am an small peanuts investor and my daughter is a customer. We had the 7+ and it just didn't work that well. It had bad range and just wasn't accurate enough. The G4 is a completely different experience. It's accuracy is dramatically improved ( usually within 15 of her meter ) and the range is amazing. I keep the receiver by my bed and it lets me know in the middle of the night whether I need to act. No more setting middle of the night alarms to go check -- this thing flat out works like a champ.

    They have made a significant breakthrough in my opinion and as word spreads, people will be buying this device in increasing #s.

    It's a gamechanger for our diabetes management. Gives me hope for what the future will hold. In an ideal world, Insulet and Dexcom merge into one and they will dominate as they clearly have 2 better moustraps.

    Sentiment: Strong Buy

  • MikeRogersJr1 by MikeRogersJr1 Dec 17, 2008 12:48 AM Flag

    My daughter is a Omnipod user. She's been using it a year and this has changed her life.

    It truly is a better mousetrap.

    Whether this company ultimately turns a profit is left to be seen, but their technology ( which is protected by numerous patents ) is very solid.

    If they don't succeed they will be bought out, in my opinion and for a lot more than they are running at right now. I'm sure the big players in the diabetes product industry would love to have this technology.

    There's nothing like it.

DXCM
40.45-1.33(-3.18%)Sep 22 4:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.